Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: VLAD who wrote (16938)	12/15/1998 8:06:00 AM
From: EyeDrMike	Read Replies (2) \| Respond to of 23519

Muse is Number One Impotence Treatment in Canada; Becomes Market Leader in Less Than Six Weeks BusinessWire, Tuesday, December 15, 1998 at 07:49 MOUNTAIN VIEW, Calif. and TORONTO, Ontario--(BW HealthWire)--Dec. 15, 1998--Canada's newest approved treatment for erectile dysfunction, MUSE(R) (alprostadil), has captured 73.4 per cent of all new prescriptions written in that category by family physicians, according to data from IMS, a company that monitors prescription sales in the pharmaceutical industry. It has taken the drug less than six weeks to become the Canadian market leader. "It's safe and patients are happy with the results," said Dr. Dominic Li, a family physician in Toronto and a Diplomat on the American Board of Internal Medicine. "I think other physicians are embracing it as a treatment option for the same reasons. It's also more pleasant to use compared to other treatments on the Canadian market." The treatment market for erectile dysfunction (ED) in Canada has grown significantly since the approval of MUSE. Overall prescriptions written in the category have increased by 60 per cent since the drug's availability, primarily as a result of GPs entering the treatment arena. More than 10,000 prescriptions have already been written for MUSE. MUSE has been popular with urologists, capturing 61.2 percent of new prescriptions written, and surging ahead of all other treatments. "There's no doubt, the single best benefit of MUSE is that it does not increase cardiovascular risk for patients," said Dr. Christian Fortin, a cardiologist from St. Lambert, Quebec. Safety continues to be one of the key issues in ED treatments, and in particular for those physicians who have patients on certain heart medications or are at other cardiac risk.